Literature DB >> 24704372

Differential modulation of GABA(A) receptor function by aryl pyrazoles.

Maria Paola Mascia1, Giovanni Ledda2, Alessandro Orrù3, Alessandro Marongiu2, Giovanni Loriga3, Elisabetta Maciocco4, Giovanni Biggio5, Stefania Ruiu3.   

Abstract

Several aryl pyrazoles characterized by a different molecular structure (flexible vs constrained), but chemically related to rimonabant and AM251, were tested for their ability to modulate the function of recombinant α1β2γ2L GABAA receptors expressed in Xenopus laevis oocytes. The effects of 6Bio-R, 14Bio-R, NESS 0327, GP1a and GP2a (0.3-30 μM) were evaluated using a two-electrode voltage-clamp technique. 6Bio-R and 14Bio-R potentiated GABA-evoked Cl(-) currents. NESS 0327, GP1a and GP2a did not affect the GABAA receptor function, but they acted as antagonists of 6Bio-R. Moreover, NESS 0327 inhibited the potentiation of the GABAA receptor function induced by rimonabant. The benzodiazepine site seems to participate in the action of these compounds. In fact, flumazenil antagonized the potentiation of the GABAA receptor induced by 6Bio-R, and NESS 0327 reduced the action of lorazepam and zolpidem. On the contrary, NESS 0327 did not antagonize the action of "classic" GABAergic modulators (propanol, anesthetics, barbiturates or steroids). In α1β2 receptors 6Bio-R potentiated the GABAergic function, but flumazenil was still able to antagonize the potentiation induced by 6Bio-R. Aryl pyrazole derivatives activity at the GABAA receptor depends on their molecular structure. These compounds bind to both an αβγ binding site, and to an α/β site which do not require the γ subunit and that may provide structural leads for drugs with potential anticonvulsant effects.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aryl pyrazoles; Aryl pyrazoles (PubChem (Ness 0327) CID 10435654); Benzodiazepines; Benzodiazepines (PubChem CID 134664); GABA(A) receptor

Mesh:

Substances:

Year:  2014        PMID: 24704372     DOI: 10.1016/j.ejphar.2014.03.039

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  A newly developed anesthetic based on a unique chemical core.

Authors:  Noëlie S Cayla; Beza A Dagne; Yun Wu; Yao Lu; Larry Rodriguez; Daryl L Davies; Eric R Gross; Boris D Heifets; M Frances Davies; M Bruce MacIver; Edward J Bertaccini
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-15       Impact factor: 11.205

2.  The Newly Synthesized Pyrazole Derivative 5-(1-(3 Fluorophenyl)-1H-Pyrazol-4-yl)-2H-Tetrazole Reduces Blood Pressure of Spontaneously Hypertensive Rats via NO/cGMO Pathway.

Authors:  Neidiane R Trindade; Paulo R Lopes; Lara M Naves; James O Fajemiroye; Pedro H Alves; Nathalia O Amaral; Luciano M Lião; Ana C S Rebelo; Carlos H Castro; Valdir A Braga; Ricardo Menegatti; Gustavo R Pedrino
Journal:  Front Physiol       Date:  2018-08-07       Impact factor: 4.566

3.  Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification.

Authors:  Anna Benini; Rossella Gottardo; Cristiano Chiamulera; Anna Bertoldi; Lorenzo Zamboni; Fabio Lugoboni
Journal:  Front Psychiatry       Date:  2021-03-18       Impact factor: 4.157

4.  Metal-assisted synthesis of unsymmetrical magnolol and honokiol analogs and their biological assessment as GABAA receptor ligands.

Authors:  Lukas Rycek; Roshan Puthenkalam; Michael Schnürch; Margot Ernst; Marko D Mihovilovic
Journal:  Bioorg Med Chem Lett       Date:  2014-11-04       Impact factor: 2.940

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.